{"id":55268,"date":"2023-03-28T17:03:05","date_gmt":"2023-03-28T15:03:05","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/pbirx-achieves-rigorous-soc-2-type-2-compliance-certification\/"},"modified":"2023-03-28T17:03:05","modified_gmt":"2023-03-28T15:03:05","slug":"pbirx-achieves-rigorous-soc-2-type-2-compliance-certification","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/pbirx-achieves-rigorous-soc-2-type-2-compliance-certification\/","title":{"rendered":"PBIRx Achieves Rigorous SOC 2 Type 2 Compliance Certification"},"content":{"rendered":"
\n

MILFORD, Conn.–(BUSINESS WIRE)–#SOC2<\/a>—PBIRx<\/a>, the premier Pharmacy Benefit Consulting firm, is proud to announce that it has earned a SOC 2 Type 2 certification, demonstrating PBIRx\u2019s commitment to integrity and protecting the privacy of clients and business partners. The certification signifies that PBIRx\u2019s information security practices, policies, procedures, and team meet the rigorous SOC 2 Type 2 security standards.\n<\/p>\n

<\/a><\/p>\n

\nData security and privacy are increasingly challenging in today\u2019s cloud-based environments. SOC 2 Type 2 audits are conducted to address any third-party risk concerns. SOC 2 certification is awarded to businesses that demonstrate their ability to meet the institute\u2019s high standards in each category and properly protect data within their data center and information systems. Building on the work already accomplished in PBIRx\u2019s SOC 2 Type 1 certification, this additional SOC 2 Type 2 certification validates the effectiveness and sustainability of data security measures over time.\n<\/p>\n

\n\u201cNow more than ever, security, integrity, and data privacy matter,\u201d said Patricia Sirowich, CEO and Founder of PBIRx. \u201cWe care deeply about the trust that our clients and business partners put in PBIRx every day. We are proud to have this SOC 2 Type 2 certification as validation of the high security standards we adhere to, not only in our technology but in our employees and processes, which are integral to all PBIRx operations.\u201d\n<\/p>\n

\nTo further assess operational effectiveness and security, going forward, PBIRx will maintain an annual SOC 2 Type 2 certification, demonstrating PBIRx\u2019s ongoing commitment to the highest level of compliance and integrity.\n<\/p>\n

\nAbout <\/b>PBIRx<\/b><\/a>\n<\/p>\n

\nOur mission is to create optimal healthcare outcomes while minimizing overall healthcare costs. Established in 1993, PBIRx serves as a premier pharmacy benefit consulting firm providing intelligent management solutions. We have deep knowledge and advanced tools, and PBIRx has built lasting relationships throughout this ever-evolving pharmacy benefit industry. With a focus on insight and service, PBIRx empowers our clients to unravel the complexities of pharmacy benefit management. We are recognized as an Inc. 5000 fastest growing company, a SOC 2 Type 2 certified company, and a certified Woman Owned Business Enterprise.\n<\/p>\n

\nPBIRx is data-driven. Our specialized team, with a diverse set of skills, put that data to work for you. IT personnel, actuaries, financial analysts, clinical pharmacists, attorneys, compliance officers, and pharmacy benefit management experts become an extension of your team, all working with a laser focus on serving you at the highest level.\n<\/p>\n

\nTo learn more, please visit PBIRx<\/a>.com and follow @pbirx<\/a> on Twitter or PBIRx<\/a> on LinkedIn.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia:
\n
Angela Cross
\n
Marketing Communications Manager
\n
across@pbirx.com<\/a>
203-882-1188, ext. 220\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

MILFORD, Conn.–(BUSINESS WIRE)–#SOC2—PBIRx, the premier Pharmacy Benefit Consulting firm, is proud to announce that it has earned a SOC 2 Type 2 certification, demonstrating PBIRx\u2019s commitment to integrity and protecting the privacy of clients and business partners. The certification signifies that PBIRx\u2019s information security practices, policies, procedures, and team meet the rigorous SOC 2 Type … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-55268","6":"format-standard","7":"category-industry"},"yoast_head":"\nPBIRx Achieves Rigorous SOC 2 Type 2 Compliance Certification - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/pbirx-achieves-rigorous-soc-2-type-2-compliance-certification\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PBIRx Achieves Rigorous SOC 2 Type 2 Compliance Certification - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"MILFORD, Conn.–(BUSINESS WIRE)–#SOC2—PBIRx, the premier Pharmacy Benefit Consulting firm, is proud to announce that it has earned a SOC 2 Type 2 certification, demonstrating PBIRx\u2019s commitment to integrity and protecting the privacy of clients and business partners. The certification signifies that PBIRx\u2019s information security practices, policies, procedures, and team meet the rigorous SOC 2 Type ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/pbirx-achieves-rigorous-soc-2-type-2-compliance-certification\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-28T15:03:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230328005247\/en\/1748386\/21\/PBIRx_logo19_Transparent.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pbirx-achieves-rigorous-soc-2-type-2-compliance-certification\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pbirx-achieves-rigorous-soc-2-type-2-compliance-certification\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"PBIRx Achieves Rigorous SOC 2 Type 2 Compliance Certification\",\"datePublished\":\"2023-03-28T15:03:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pbirx-achieves-rigorous-soc-2-type-2-compliance-certification\\\/\"},\"wordCount\":423,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pbirx-achieves-rigorous-soc-2-type-2-compliance-certification\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230328005247\\\/en\\\/1748386\\\/21\\\/PBIRx_logo19_Transparent.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pbirx-achieves-rigorous-soc-2-type-2-compliance-certification\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pbirx-achieves-rigorous-soc-2-type-2-compliance-certification\\\/\",\"name\":\"PBIRx Achieves Rigorous SOC 2 Type 2 Compliance Certification - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pbirx-achieves-rigorous-soc-2-type-2-compliance-certification\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pbirx-achieves-rigorous-soc-2-type-2-compliance-certification\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230328005247\\\/en\\\/1748386\\\/21\\\/PBIRx_logo19_Transparent.jpg\",\"datePublished\":\"2023-03-28T15:03:05+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pbirx-achieves-rigorous-soc-2-type-2-compliance-certification\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pbirx-achieves-rigorous-soc-2-type-2-compliance-certification\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pbirx-achieves-rigorous-soc-2-type-2-compliance-certification\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230328005247\\\/en\\\/1748386\\\/21\\\/PBIRx_logo19_Transparent.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230328005247\\\/en\\\/1748386\\\/21\\\/PBIRx_logo19_Transparent.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pbirx-achieves-rigorous-soc-2-type-2-compliance-certification\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PBIRx Achieves Rigorous SOC 2 Type 2 Compliance Certification\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"PBIRx Achieves Rigorous SOC 2 Type 2 Compliance Certification - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/pbirx-achieves-rigorous-soc-2-type-2-compliance-certification\/","og_locale":"en_US","og_type":"article","og_title":"PBIRx Achieves Rigorous SOC 2 Type 2 Compliance Certification - Pharma Trend","og_description":"MILFORD, Conn.–(BUSINESS WIRE)–#SOC2—PBIRx, the premier Pharmacy Benefit Consulting firm, is proud to announce that it has earned a SOC 2 Type 2 certification, demonstrating PBIRx\u2019s commitment to integrity and protecting the privacy of clients and business partners. The certification signifies that PBIRx\u2019s information security practices, policies, procedures, and team meet the rigorous SOC 2 Type ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/pbirx-achieves-rigorous-soc-2-type-2-compliance-certification\/","og_site_name":"Pharma Trend","article_published_time":"2023-03-28T15:03:05+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230328005247\/en\/1748386\/21\/PBIRx_logo19_Transparent.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/pbirx-achieves-rigorous-soc-2-type-2-compliance-certification\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/pbirx-achieves-rigorous-soc-2-type-2-compliance-certification\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"PBIRx Achieves Rigorous SOC 2 Type 2 Compliance Certification","datePublished":"2023-03-28T15:03:05+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/pbirx-achieves-rigorous-soc-2-type-2-compliance-certification\/"},"wordCount":423,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/pbirx-achieves-rigorous-soc-2-type-2-compliance-certification\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230328005247\/en\/1748386\/21\/PBIRx_logo19_Transparent.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/pbirx-achieves-rigorous-soc-2-type-2-compliance-certification\/","url":"https:\/\/pharma-trend.com\/en\/pbirx-achieves-rigorous-soc-2-type-2-compliance-certification\/","name":"PBIRx Achieves Rigorous SOC 2 Type 2 Compliance Certification - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/pbirx-achieves-rigorous-soc-2-type-2-compliance-certification\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/pbirx-achieves-rigorous-soc-2-type-2-compliance-certification\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230328005247\/en\/1748386\/21\/PBIRx_logo19_Transparent.jpg","datePublished":"2023-03-28T15:03:05+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/pbirx-achieves-rigorous-soc-2-type-2-compliance-certification\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/pbirx-achieves-rigorous-soc-2-type-2-compliance-certification\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/pbirx-achieves-rigorous-soc-2-type-2-compliance-certification\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230328005247\/en\/1748386\/21\/PBIRx_logo19_Transparent.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230328005247\/en\/1748386\/21\/PBIRx_logo19_Transparent.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/pbirx-achieves-rigorous-soc-2-type-2-compliance-certification\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"PBIRx Achieves Rigorous SOC 2 Type 2 Compliance Certification"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55268","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=55268"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55268\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=55268"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=55268"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=55268"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}